Concomitant Use of Central Nervous System Stimulants and Depressants Prescribed in Rhode Island by Babcock, Aram
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2017 
Concomitant Use of Central Nervous System Stimulants and 
Depressants Prescribed in Rhode Island 
Aram Babcock 
University of Rhode Island, arambabcock@uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Babcock, Aram, "Concomitant Use of Central Nervous System Stimulants and Depressants Prescribed in 
Rhode Island" (2017). Open Access Master's Theses. Paper 1054. 
https://digitalcommons.uri.edu/theses/1054 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
 CONCOMITANT USE OF CENTRAL NERVOUS SYSTEM STIMULANTS  
AND DEPRESSANTS PRESCRIBED IN RHODE ISLAND 
BY 
ARAM BABCOCK 
 
 
 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
PHARMACEUTICAL SCIENCES 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2017 
 MASTER OF SCIENCE THESIS 
OF 
ARAM BABCOCK 
 
 
 
   
APPROVED: 
   THESIS COMMITTEE: 
   MAJOR PROFESSOR: Xuerong Wen 
       Stephen Kogut 
       Natallia Katenka 
       Nasser Zawia 
     DEAN OF THE GRADUATE SCHOOL  
 
 
UNIVERSITY OF RHODE ISLAND 
2017 
 
 
 
 
ABSTRACT 
Background: Risks of morbidity and mortality may arise when prescription 
stimulants are used in combination with prescription central nervous system 
(CNS) depressants. The RI Prescription Drug Monitoring Program (PDMP) 
captures all prescriptions for schedule II to IV, as well as information on certain 
schedule V medications. 
Objective: This study examines the pattern of using a combination of controlled 
substance prescription CNS stimulants with CNS depressants in RI.  We also seek 
the predictors of concomitant use of these two drugs classes in patients. 
Methods: This was a cross-sectional study using de-identified data from the RI 
PDMP in 2015. We included all patients who filled a prescription for stimulants 
or CNS depressants. Medications that are not in these two study drug classes were 
excluded. The outcome of interest was concomitant use of stimulants and CNS 
depressants, which was defined as patients who filled any stimulants and any 
depressants with at least 60 days of combined fill and less than 15 days’ gap in 
filling.   Demographic characteristics of patients were used in the statistical 
analyses to identify the predictors of concomitant use of stimulants and 
depressants.  
Results: In the complete RI PDMP data set, there was a total 409,740 patients 
 who filled 2,516,314 prescriptions of schedule II to V medications. The patients  
using both stimulants and CNS depressants tended to be younger females, which 
 used private pay (cash) more frequently than their male counterparts. Patients 
 in the stimulants and CNS depressants cohort were older women who used 
 
 
 
 
 commercial pay type at a higher percentage than their counterparts in the stimulants only 
cohort.  A difference existed in the percent of patients that filled an average days’ supply 
of less than or equal to 30 days compared with greater than 30 days, between those who 
take both prescription controlled substance stimulants and depressants chronically 
compared with those who fill only stimulants. In hypothesis 3, patients in the Attention 
Deficit Hyperactivity Disorder cohort were younger with a lower percentage average 
daily dose (less than or equal to 25 milligrams) of stimulant, more likely to be of male 
sex, and use commercial insurance as the primary pay type compared to the usage of 
stimulants in the stimulants and CNS depressants cohort. 
Conclusion: The prevalence of chronic concomitant therapy of stimulants with 
CNS depressants was associated with prescribing longer days of supply and higher 
dose of stimulants. The most prevalent pay type of all cohorts was commercial 
insurance.  
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CHAPTER 1 
INTRODUCTION 
The most commonly prescribed medications for Attention-
Deficit/Hyperactivity Disorder (ADHD) in adults in the United States are the 
controlled substance stimulant class of medications, including amphetamine salt 
and methylphenidate.1 Common adverse effects associated with these medications 
include irritability, anxiety, and difficulty falling asleep or staying asleep.2 To 
combat the aforementioned adverse effects, patients may be prescribed central 
nervous system depressants which can slow down the central nervous system and 
reduce the stimulant adverse effects.3,4 Included in these medication classes are 
tranquilizers, barbiturates/sedatives, muscle relaxants and other prescription 
sedatives such as zolpidem, eszopiclone and zaleplon. Their desirable side effects 
or undesirable adverse effects often include: drowsiness, dizziness, tiredness, or in 
more severe cases respiratory depression leading to coma and death.3,4 The 
combination of stimulants and depressants, however, can cause mixed signals 
within the brain, and can lead to adverse events including coma and death.4 
A 2015 National Survey of Drug Use and Health (NSDUH) surveyed the 
use and misuse of individual medications in the four groups separately, but not in 
concomitant use with medications from the other groups.1  We analyzed potential 
signs of misuse by way of comparing overutilization of controlled substances in 
combination according to the definitions from the Center for Medicare and 
Medicaid Services (CMS)5 and the Center for Disease Control.6 Overutilization has 
also been termed polypharmacy, or use of more than one pharmacy to fill a 
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prescription, or an inappropriate medication regimen. Adverse outcomes from 
unnecessary over-prescribing of medications, particularly in the elderly, may occur 
from this practice.7-9 In addition, there is concern for patients of all ages who have 
taken prescribed stimulants with non-prescribed controlled substances.10-16 By 
creating awareness of the prevalence and potential risk factors of this type of 
antagonistic medication usage, prescribers may be able to target at-risk populations 
more readily to avoid potential adverse outcomes. 
To-date there has been no published study conducted with information from 
the Rhode Island State Prescription Drug Monitoring Program (PDMP) which 
describes chronic concomitant therapy of prescription stimulants with prescription 
depressants.  This study sought to discover if there are significant risk factors 
associated with patients using a combination of prescription central nervous system 
(CNS) stimulants with prescription CNS depressants based on the demographic 
characteristics provided by the data source, including age, sex, and payment type.   
To better understand the relationship among different subpopulations 
represented by claims in the RI PDMP and how their baseline demographics and 
fill history affect the combined use of CNS stimulants and depressants, three 
hypotheses were developed: 
1. There is no difference in baseline characteristics among patients of combination use 
of stimulants and CNS depressants in consideration of days of concomitant use. 
2. There is no difference in the percentage of patients’ average days of supply of 
either less than and equal to 30 days or more than 30 days for those who 
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chronically fill only a prescription stimulant compared with those who fill 
prescriptions stimulant(s) with a depressant(s). 
3. For those who chronically fill the two most commonly prescribed medication bases 
for ADHD, there is no difference in the percentage of average daily dose of either 
less than or equal to 25 milligrams or more than 25 milligrams for patients taking 
only the ADHD medication base compared with those taking both ADHD 
medication base stimulants and depressants. 
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CHAPTER 2 
REVIEW OF THE LITERATURE 
A paucity of data exists for legally prescribed use of combinations of 
central nervous system stimulant and depressant medications in the primary care 
setting, while information is more readily available from small patient clinical trials 
of patients with a history of drug abuse.17-21 More information exists in the 
literature about non-medical users of these CNS medications than of those taking 
them as prescribed.10-16 However, adverse outcomes such as emergency department 
visits, hallucinations, coma, death, may still occur for both populations. In addition, 
there is a concern for when one controlled substance is used to treat adverse effects 
of another controlled substance, as proposed by the Drug Enforcement Agency’s 
2015 resource guide.4 Stimulants such as modafinil and methylphenidate can 
reduce sedative effects caused by opioids and other CNS depressants.22 When used 
appropriately, this practice can be clinically useful for patients utilizing opioids 
who feel overly sedated and in the hospice or palliative care setting, but data are 
lacking to support this practice for adolescents or older patients in the primary care 
setting.22-24  Additionally, clinical guidelines from the American Pain Society make 
no recommendation for the use of any stimulant or other medication for the 
treatment of opioid-induced sedation.25 Sedatives/hypnotics and tranquilizers may 
be used to reduce the stimulant effects of nervousness, restlessness, and difficulty 
falling asleep or staying asleep.4 Risk of morbidity and mortality may arise when 
stimulants are used in combination with central nervous system depressants 
because this combination can lead to adverse outcomes including hospitalizations, 
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coma, and death, even at properly prescribed doses.4  Properly prescribed doses 
refers to a physician prescribing in the usual course of his/her practice, while 
staying within FDA-approved maximum daily dosages. 
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CHAPTER 3 
METHODOLOGY 
Research design: 
A cross-sectional study was conducted using de-identified data from the RI 
Prescription Drug Monitoring Program (PDMP) for 2015.  This study evaluated 
patterns of combined use CNS stimulant and depressant controlled substance 
medications in the State of Rhode Island in schedules II, III, IV, and some data on 
schedule V, as defined by the Controlled Substances Act Code of Federal 
Regulations Title 21.26 The PDMP data includes all Schedule II to IV prescription 
medications, some schedule V medications, and some non-controlled 
medications, dispensed by RI pharmacies. All pharmacies with a RI controlled 
substance registration (CSR) number are required by regulation to file a report on 
all controlled substances filled within 72 hours of the prescription being dispensed 
to the patient. The data provided by the Rhode Island Department of Public 
Health for this project included the following information: patient de-identified 
number, patient age (years), patient’s gender, prescriber de-identified number, 
dispensing pharmacy de-identified number, date dispensed, National Drug Code 
(NDC) for the drug, drug name, drug strength, formulation, therapeutic class 
code, days of supply, metric quantity dispensed, and method of payment. 
General Characteristics of the study population: 
Inclusion criteria: 
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All study participants who filled a prescription at a Rhode Island pharmacy in the 
calendar year of 2015 for at least one controlled substance stimulant as well as at 
least one controlled substance depressant in the 2015 calendar year were included. 
Medications included in the study were grouped into one of ten categories.  These 
categories were defined by a variable provided within the data set which indicates 
the therapeutic class code, which is used to differentiate medications based on 
their primary therapeutic use.  The medications were then placed into broader 
groups based upon the primary effect of the base component(s) of the 
medications.  Stimulants consisted of medications that could generally be 
considered of use for weight-loss therapy, narcolepsy, or Attention Deficit 
Hyperactivity Disorder. Examples including, but not limited to were: 
phentermine, modafinil, and mixed amphetamine salts. CNS depressants 
consisted of medications that could generally be considered of use for pain 
mitigation (opioids), cough, sleep disturbance (sedative/hypnotic/tranquilizer), 
migraines or sedation (barbiturates), neuropathic pain, or skeletal muscle 
spasms/pain. Examples including, but not limited to, were: oxycodone, 
hydrocodone, codeine, benzodiazepines (lorazepam, alprazolam, others), 
zolpidem, carisoprodol, pregabalin, and butalbital. If the medication contained 
both stimulant and depressant effects, grouping preference was given to 
whichever component had characteristics which corresponded to a lower schedule 
(as defined by the Controlled Substances Act).  Analysis was based on de-
identified PDMP data collected in 2015 in the State of Rhode Island.   
Exclusion criteria: 
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Claims for medications that are not controlled substances were excluded from 
analyses. Claims for medications that were for hormonal replacement were 
excluded. Hypothesis 2 further reduced the population by three patients based 
upon outliers.  Hypothesis 3 further reduced the population by removal of all but 
two stimulant bases, and any non-oral ADHD stimulant (methylphenidate patch). 
Index date: 
The index date was defined as the first day of overlapping prescription fill date 
based on a claim beginning January 1, 2015 and ending December 31, 2015.   
Dependent Variables (outcomes): 
In hypothesis 1, the dependent variable was chronic concomitant therapy, which 
was deemed “overlap”. Overlap was defined as filling one or more stimulants 
with one or more depressants with 60 or more consecutive days of supply with no 
gaps >15 days.   This definition was chosen based on a previous study that 
suggested a minimum of 61 days, where by most instances of cross-titration were 
not misidentified as polypharmacy.27 As indicated in this study’s definition, the 
one extra day was included (60 vs. 61). In hypothesis 2, the dependent variable 
was average days of supply, which was binarized to either less than or equal to 30 
days or more than 30 days.  Thirty days was chosen based upon mean values for 
the cohorts, as well as a clinically significant length for days supply.  Many 
prescriptions written for patients on chronic therapy of many diseases have their 
prescriptions written, and filled for, thirty-day periods.  This variable was 
formulated by totaling each patients’ days of supply for each claim and dividing it 
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by 365 days.  In hypothesis 3, the dependent variable was average total daily dose 
of the ADHD stimulant medication, which was binarized to either less than or 
equal to 25 milligrams or more than 25 milligrams. Twenty-five milligrams was 
chosen as a cut-off based upon a median value from the cohorts. This variable 
was derived by multiplying the per unit dosage strength of each medication by the 
number of dosage units, and then dividing by the days supply. Dichotomous 
variables were created because the sample sizes were large enough to do so, while 
also being able to create relevant cutoffs for better interpretation with odds ratios 
rather than β-coefficients. 
Independent variables (exposures): 
Independent variables included patient’s age, gender, and payment type.  Age is 
given in whole year increments, with the first age at occurrence of claim was 
used.  Gender is given as male or female, with the first gender at occurrence of 
claim was used.  Payment type, using the first occurrence of the claim, included 
three categories: government/other, private pay, and commercial insurance.  
Government/other pay type was comprised of several payers including Medicaid, 
Medicare, Military Institution or Veterans’ Administration, Workers’ 
Compensation, Indian Nations, and ‘other’, as given by the data set. 
Descriptive Analysis: 
An analysis for individuals in the age groups of (1) younger than 12, (2) 12-17, 
(3) 18-25, (4) 26-64, and (5) 65 or older, which is similar to how the NSDUH 
survey differentiated age groups (12-17, 18-26, 26+).1 This study also examined 
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the effects of gender on concomitant drug use.  The patient’s first gender entered 
into the PDMP data file was used.  The patient’s first age in the PDMP was used. 
A comparison of the different payment types (cash, private, or government/other) 
was also be conducted. The first payment type for each patient was used. 
Statistical analysis: 
Statistical analyses included chi-square test or Fisher’s Exact test to compare the 
differences between two categorical variables and multivariate logistic regression 
to discover any significant predictors for overlapping or concomitant therapy, as 
defined in the Methodology section. The age comparison for hypothesis 1 was 
performed using simple averaging of ages of all unique patients, using the age at 
first claim given in the PDMP, in the overlap compared with no overlap cohort.  
The student t-test was used to compare the two independent cohorts, with age as a 
continuous variable.  A frequency procedure was used to determine overall 
percentages for gender and pay type, using the first gender given in the PDMP for 
each unique patient, within the stimulants and depressants and stimulants-only 
patients. A 30-day cut-off period was used to dichotomize the population based 
on the median value of all the average days of supply for hypothesis 2. This 
analysis was conducted using a test in the difference of means of two independent 
samples using a t-test, with days’ supply as a continuous variable.  Similarly, 
hypothesis 3 was dichotomized based on median of the average daily dose of 
ADHD stimulants of 25 mg. Due to the unbalanced sample size in two 
comparison groups, we examined the variance equity for student t test. We chose 
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chi square test to compare the categorical variables since the sample size is large. 
Analysis was conducted using SAS Version 9.4 (SAS Institute, Inc., Cary, NC). 
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CHAPTER 4 
RESULTS 
The first hypothesis includes the population of patients within the RI 
PDMP which had claims for both a stimulant and depressant (Figure 1, 
N=131,476) at any point during the 2015 calendar year.  This population was 
further narrowed to those patients with claims for both a stimulant and 
depressant(s) for at least one day (N=4,791).  Further, the population was then 
defined as having concomitant stimulant and depressant use if their days of 
overlap was 60 days or more, with no more than a 15-day gap in claims 
(N=4,389), indicating a 1.1% prevalence among unique patients captured by the 
PDMP.  The two populations ultimately compared were those with the 60 days’ 
overlap (<15-day gap, N=4,389, Overlap Yes) to those with overlap of zero to 59 
days’ supply (N=127,087, Overlap No).  The two cohorts’ baseline characteristics 
are listed and compared in Table 1.   
The Overlap Yes cohort had a mean age of 43.3 years with a standard 
deviation of 13.1 years.  The Overlap No cohort had a mean age of 48.6 years 
with a standard deviation of 21.2 years.  When compared, this resulted in a two-
sided p-value of < .0001, representing a statistically significant difference 
between the two cohorts.  The results show that patients within the Overlap Yes 
group tended to be younger in age from the Overlap No cohort by about five 
years, with a smaller standard deviation from this mean age. 
Within the Overlap Yes cohort of patients, females accounted for 67.9% 
(N=2,979) of the patients, while men accounted for 32.1% (N=1,410).  In the 
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Overlap No cohort, females accounted for 57.8% (N=73,401), while the men 
accounted for 42.2% (N=53,670).  When compared using the Chi Square Test, the 
two-sided p-value was < .0001, representing a significant difference between 
females’ and males’ percentages between Overlap Yes and Overlap No cohorts. 
Females were more likely to fill both a stimulant and a depressant throughout the 
year, regardless whether overlap occurred. 
The final variable examined in the baseline characteristics was pay type.  
Data entry for the pay types from the RI PDMP originally contained eight 
different pay codes.  This study simplified the eight pay codes into three pay 
types: private pay (cash purchase), government payer/Other (Medicaid, Medicare, 
Military institution or Veterans Affairs, Indian Nations, Workers’ Compensation, 
or Other), and Commercial insurance.  The first occurrence was taken for each 
unique patient given by the PDMP.  The Overlap Yes cohort had a higher 
percentage of private pay than did Overlap No.  The Overlap No cohort had 
higher percentages of Government payer/other payer and Commercial insurance.    
In both cohorts, Commercial Insurance had the highest percentage of pay type 
used for payment of claims, followed by private pay, then government/other pay 
type.  These differences were significant for this discrete variable, as indicated by 
a p-value of < .0001. 
In summary, the patients in the Overlap Yes cohort tended to be younger 
females, which used private pay (cash) more frequently than their Overlap No 
counterparts, while the most frequent pay type for both cohorts was commercial 
insurance. 
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 The second hypothesis was aimed at whether the percent of 
patients who filled for less than or equal to 30 days compared with more 
than 30 days differed between the stimulants and depressants cohort and 
that of those who only filled stimulants.  In other words, are those who fill 
both types of medications more likely to take medication for a longer 
period than those who fill only stimulants?  Figure 2 displays a flow chart 
for the cohorts.  The original stimulants and depressants cohort contained 
4,389 patients, as noted in hypothesis 1.  However, while performing a 
baseline test for normality, three patients were considered outliers, 
identified as their average days’ supply exceeded 100 days.  These outliers 
consisted of three patients which had an average days’ supply of 110, 120, 
or 400. Removal of the outliers reduced the population of the cohort to 
4,386.  The outliers more than doubled the standard deviation (outliers= 
6.76 vs. no outliers= 3.3) in the average days of supply. No patients within 
the stimulants-only cohort were considered outliers based on the average 
100 days’ supply definition. The stimulants only cohort consisted of 
37,982 unique patients. Table 2 shows the characteristics of the cohort 
with the removal of the three outliers, which was the cohort used for 
analysis. 
Mean age in the stimulants and depressants cohort was 43.4 years 
with a standard deviation of 13 years.  The mean age of the stimulants 
only cohort was 29.3 years with a standard deviation of 17 years.  As 
compared by the t-test, the p-value for this difference between the two 
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cohorts was < .0001, showing a statistical significance.  The patients in the 
stimulants only group tended to be about 14 years younger with a larger 
standard deviation.  
The stimulants and depressants cohort contained about a 2:1 ratio 
of female to male patients, with females making up 67.9% of this 
population, reflecting the hypothesis 1 baseline characteristic.  The 
stimulants only cohort contained almost a 1:1 ratio, with females making 
up a slightly higher percentage than the males.  The difference between 
these two cohorts was tested using the Chi Square Test for Homogeneity, 
with a resulting p-value of < .0001, indicating a significant difference 
between the stimulants and depressants and stimulants only cohorts 
regarding gender, where women constituted a higher percentage than men 
in the stimulants and depressants cohort. Pay types were also 
significantly different between the two cohorts with a p-value of < .0001 
based on the Chi Square Test for Homogeneity. Although they were not 
similar with their individual percentages of which pay type, the two 
cohorts were similar in their most commonly used pay types. The most 
commonly used form of payment in order of most used to least used was: 
commercial, private (cash), and then government/other payer. These 
results indicate once again, that commercial insurance is the primary payer 
for these two cohorts based on chronic use. In addition, two patients did 
not have information on pay type. Due to this loss of pay type data for two 
patients, there are slight differences in pay type percentages as compared 
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to the cohort in hypothesis 1. In comparison, the stimulants only cohort 
had a higher percentage of commercial payers compared with the other 
cohort, while also exhibiting lower percentages of government/other payer 
and private (cash) payers. 
 Determining difference in day of supply between the stimulants 
and depressants and stimulants only cohorts was the primary objective of 
this hypothesis. Figure 3 shows post-removal of outlier data including 
breakdown of the population. The stimulants and depressants cohort had a 
mean days of supply of 29.7 days and a standard deviation of 3.3 days of 
supply. Similarly, the stimulants only cohort had a mean days of supply of 
29.6 days and a standard deviation of 3.8 days. Because both cohorts had 
an average days of supply of about 30 days and 30 days is a common days 
supply for patients filling a chronic medication on a monthly basis, this 
timeframe was chosen to later dichotomize the cohorts and compare using 
a chi-square test. The difference by percentage in average days of supply 
was significant, as showcased by the p-value of <.0001 shown in Figure 3. 
We reject the null hypothesis because the p-value (<.0001) is ≤ α (0.05), 
indicating that the population variances are significantly different. 
Because the variances are unequal, the Satterthwaite t-value (0.2099) is 
used. Therefore, there is a difference in days of supply between those who 
take both stimulants and depressants chronically compared with those who 
fill only stimulants by percentage. 
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A multivariable logistic regression was performed on the baseline 
characteristics and overlap to see if there were any predictors for when the 
patients filled with a higher percentage to have an average days’ supply 
less than or equal to 30 days. The average days’ supply given in binary 
terms was the dependent variable, while the, age, gender, pay type, and 
whether the patient was in the overlap cohort (stimulants and depressants 
or stimulants only), were the independent variables. Based on the 
dependent variable, 42,050 patients were identified in the less than or 
equal to 30 days’ average supply cohort, leaving the remaining 316 
patients in the greater than 30 days’ average supply cohort.  
Age was transformed into a discrete number of categories, instead 
of leaving it as a continuous variable. Age was re-categorized into </= 11, 
12-17, 18-25, 26-64, and > 64 years of age. These age groups are 
reflective of the categories in the NSDUH survey.1 Reference values 
included stimulants only, age 18-25, male gender, and government/other 
payer. Significant patient predictors included all age categories compared 
to the reference age category, as well as private pay (cash) type. The 
patient predictors which were not significant included overlap usage, 
gender, and commercial pay type. 
Odds ratio (OR) estimates with their corresponding confidence 
intervals of 95% and p-values are given in Table 5. The maximum 
likelihood estimates along with Akaike’s information criterion (AIC) is 
also provided in Table 4 for both crude and adjusted models. The OR 
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point estimates were obtained by exponentiating each of the parameter 
estimates, where e^β.28 The OR results show that age younger than 18-25 
are over three times the risk of having filled an average days’ supply of 
less than or equal to 30 days (</=11: OR=3.054, 95% CI= (1.412,6.603), 
p-value= 0.0045, 12-17: OR=3.118, 95% CI= (1.542,6.304), p-value= 
0.0015), while those older than the 18-25 reference group were between 
43% and 85% less likely to fill for less than an average of 30 days’ supply 
(26-64: OR=0.57, 95% CI= (0.397,0.82), p-value= 0.0024, >64: 
OR=0.153, 95% CI= (0.098, 0.24), p-value= <.0001). The cohort of 
patients who used private (cash) pay type had lower odds of filling an 
average days’ supply of less than or equal to 30 days’ supply (vs 
government/other: OR=0.575, 95% CI= (0.399,0.829), p-value= 0.003), 
showing about a 42% decrease in odds of using this pay type when filling 
for less than or equal to 30 days. No difference in odds appeared in 
whether the two cohorts used commercial pay type compared with a 
government/other payer. Based on the model inputs, the Hosmer and 
Lemeshow Goodness-of-Fit Test p-value was 0.8222, indicating a good fit 
for the model. 
In summary, the patients in the stimulants and depressants cohort 
were older women who used commercial pay type at a higher percentage 
than their counterparts in the stimulants only cohort. Also, there was a 
difference in the average of days’ supply of less than or equal to 30 days 
compared with greater than 30 days, between those who take both 
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stimulants and depressants chronically compared with those who fill only 
stimulants. The binary logit model appears to indicate an acceptable level 
of fit. 
The study population within hypothesis 3 was a smaller cohort derived 
from the stimulants only cohort in hypothesis 2, as indicated in Figure 4. The 
baseline characteristics are given in Table 4. The mean age for the ADHD-stims 
cohort was 27 with a standard deviation of 16 years, while the mean age and 
standard deviation for stimulants and depressants was 42 and 13, respectively. 
The ADHD stimulants cohort consisted of a significantly higher percent of males 
(52%) compared with the stimulants and depressants cohort (32.5%), as measured 
by chi square p-value of < .0001. Pay types were also significantly different 
between the two cohorts. Commercial insurance was used 70% of the time in the 
ADHD-stimulants cohort compared to 48% with the stimulants and depressants 
cohort, also measured by p-value <.0001. 
The seven most commonly prescribed ADHD stimulants based on total 
claims from the RI PDMP in 2015 are shown in Figure 5. The two main 
medication groups studied were stimulants and CNS depressants (Table 6). 
However, only mixed amphetamine salts-based and methylphenidate-based 
medications were included in this hypothesis as a subpopulation of interest, 
deemed ADHD-stimulants. These medication bases were chosen because the 
2015 NSDUH stated that they were the two most commonly prescribed stimulant 
bases for ADHD in 20151. Bases refers to the underlying active ingredient, 
disregarding any corresponding brand names. The population breakdown and 
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average daily dose in milligrams(mg) is given in Figure 6, comparing the ADHD-
stims cohort with the stimulants and depressants cohort. The ADHD-stimulants 
cohort had an average daily dose of 29 mg, while the cohort averaged 39 mg.   
The multivariate logistic regression compared the ADHD-
stimulants cohort to that of stimulants and depressants cohort in a similar 
manner as in hypothesis 2. As such, odds ratios (OR) were measured upon 
the same variables of sex, age by group, and pay type. However, because 
this hypothesis was based on average daily dose, the dependent variable 
was dichotomized based on an average daily dose; less than or equal to 25 
mg or greater than 25 mg. This dichotomization reflected the median 
average daily dose for the ADHD-stims cohort (24.5 mg). Reference 
values included ADHD-stims, age 18-25, male gender, and 
government/other payer.  Significant patient predictors cohort, sex, ages 
less than 18 or age 26 to 64, and private pay type. The patient predictors 
which were not significant included age greater than 64 and commercial 
pay type. 
Odds ratio estimates with their corresponding confidence intervals 
of 95% and p-values are given in Table 6. The maximum likelihood 
estimates along with Akaike’s information criterion (AIC) is also provided 
in Table 6 for both crude and adjusted models.  The OR results show that 
females had a 24% increase in odds (vs. males: OR= 1.244, 95% CI= 
(1.185,1.305), p-value= <.0001). Patients aged </=11 compared with age 
18-25 had four times greater odds or three times increased risk 
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(OR=4.109, 95% CI= (3.747,4.505, p-value= <.0001), and those aged 12-
17 compared with 18-15 had a 32% increase in odds (OR=1.326, 95% CI= 
(1.229,1.43), p-value= <.0001) of filling less than 25 mg average daily 
dose of stimulants. The OR results show that the S&D cohort had 44% 
decreased odds of filling less than 25 mg for their average daily dose (vs. 
ADHD-stims: OR=0.561, 05% CI= (0.518,0.608), p-value= <.0001). 
Private (cash) payers compared with government/other payers had 25% 
decreased odds (OR=0.752, 95% CI= (0.691,0.819), p-value= <.0001) of 
filling 25 mg average daily dose. Patients aged 26-64 compared with 18-
25-year-old patients had a 35% decrease in odds (OR=0.647, 95% CI= 
(0.608,0.688), p-value= <.0001) of filling for 25 mg average daily dose. 
The Hosmer and Lemeshow Goodness-of-Fit Test p-value was 0.0111, 
indicating a less than acceptable level of fit for the model. 
 In summary, the ADHD-stimulants cohort was younger, had a 
lower average daily dose of stimulant, more likely to be of male sex, and 
use commercial insurance as the primary pay type compared to the 
stimulants and depressants cohort. However, the Goodness-of-Fit Test 
showed a less than acceptable level of fit for the model. 
  
 
 
22 
 
CHAPTER 5 
DISCUSSION 
Over 400,000 patients filled more than 2.5 million prescriptions, captured 
by the RI PDMP for calendar year 2015. In all hypotheses, the number of patients 
falling under the overlap definition was far fewer than the comparative cohorts. 
The patients in the overlap cohort in hypothesis 1 tended to be younger women, 
who used commercial insurance more frequently than their counterparts. Patients 
in hypothesis 2 in the stimulants and depressants cohort were mostly older women 
(mean age 43.4 years old +/- 13 years) who used commercial pay type at a higher 
percentage than their counterparts in the stimulants-only cohort. A difference 
existed in the percent of patients who filled for an average of days’ supply of less 
than or equal to 30 days compared with greater than 30 days between those who 
filled both stimulants and depressants chronically compared with those who filled 
only stimulants. The stimulants only cohort was younger, on average, possibly 
because ADHD stimulants are primarily prescribed to younger patients. The 
average age at onset of ADHD is seven years old, while ADHD symptoms often 
improve for many people with increasing age.29 However, this hypothesis also 
contained stimulants for diagnoses other than ADHD, including weight loss and 
narcolepsy. 
Hypothesis 3 was based on a subpopulation of hypothesis 2. The ADHD-
stimulants cohort was younger with a lower average daily dose of stimulant, more 
likely to be males, and use commercial insurance as the primary pay type 
compared to the usage of stimulants in the S&D cohort. Research supports the 
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finding that the ADHD stimulants cohort should be comprised of mostly younger 
males as reported by Merikangas et al.30 This study reported that males 13-18 
years of age have a lifetime prevalence of 12.9% compared with females 13-18 
years of age of 4.9%, with children 13-18 having an overall lifetime prevalence 
higher than adults.31 In the State of Rhode Island, children aged 4-17 having ever 
been diagnosed with ADHD rose steadily from year 2003 to 2007 to 2011, with 
corresponding percentages of  9.8, 11.1 and 13.4%, respectively.31 Children in 
Rhode Island in a similar age group (4-17 years old) which were reported by a 
parent as currently diagnosed with ADHD, also revealed that these children had a 
higher than average current diagnosis percentage (2011: RI 11.1% vs. U.S. 8.8%) 
and a higher percentage of children taking ADHD medication (2011: RI 6.3% vs. 
U.S. 6.1%) as compared to the average of all children in the United States.32 
By focusing on the two most commonly prescribed stimulants, which were 
also estimated to be the two most prescribed medications for ADHD1 in 2015, we 
sought whether patients using these two medications differed from those filling a 
combination of ADHD stimulants and depressants. The results showed that those 
in the stimulants only cohort had a lower percent for their average daily dose 
below 25 mg. This could have been for several reasons. One reason may be that 
younger patients may not require as high a dose as older patients based on 
severity of disorder or disease. Research indicates ADHD symptoms only persist 
in about half of patients into adulthood.33,34 This 50% could be the more severe 
cases of patients, who then may require higher doses of the ADHD stimulants 
later in life. In addition, a study by Merikangas et al reported that children 13-18 
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years old have a 1.8% lifetime prevalence of severe ADHD, while Kessler et al 
reported that adults have a 1.7% lifetime prevalence of severe ADHD.30,35 
Another possibility is that older patients may develop greater tolerance over the 
course of their lifetime or therapy and require higher doses over time. Tolerance is 
defined by the National Institute on Drug Abuse as “when the person no longer 
responds to the drug in the way that person initially responded”.36 Another reason 
may be that those patients filling depressants may need higher doses of stimulants 
to counteract the sedating effects of the depressants, hypothesized once again, due 
to tolerance. In this situation, a concern can be raised that as patients require 
higher doses of CNS depressants, they may also treat the worsening of adverse 
effects with stimulants. For example, a patient may become tolerant to their 
opioid and begin to escalate their dose to cover their increase in pain. As the 
patient does this, they may also experience more sedating effects from the opioid. 
To counter those effects the patient may begin taking more of a (prescribed) 
stimulant, which helps keep them awake, alert, and/or capable of performing their 
usual daily tasks. Unfortunately, the patient may reach a tipping point where the 
self-medicating titration of the combination exposes the patient to a toxic level of 
one, either, or both medications. In the case of an opioid, this may result in 
respiratory depression, coma, or death, as referenced above.3,4 
A limitation of this study is lack of certain patient health information, 
primarily diagnosis codes. Initial diagnosis(es) of patients’ health conditions were 
not recorded, nor were pertinent other medications which may lead to a better 
understanding of severity of the patients’ disorders. A difference in percent of 
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average daily dose could simply be due to severity of mental illness or learning 
disability. A differential diagnosis should rule out major depression, bipolar 
disorder, generalized anxiety, substance abuse or dependence, or personality 
disorders.37 For example, a patient with a more debilitating form of ADHD may 
require higher doses of their stimulant to reduce the symptoms of their disease. 
Additionally, data within the PDMP did not differentiate human from animal 
claims data. As such, it is believed that a small portion of the claims may have 
included animal patients, which may have influenced the number of private pay 
claims.   
By choosing the first claim for each patient to specify age, gender, and 
paytype, there is a possibility of misrepresenting the patients’ true demographics. 
For instance, if a pharmacy placed a claim for a female as male for the first claim, 
but later corrected it for the other fills, the corrected gender would not be 
represented. By choosing the patients’ first age, there may have also been a 
tendency to have an overall younger population. Following gender and age, 
paytype may have also been biased towards one payment type over the others and 
may account for the large percentage of cash payers. One explanation for this is if 
the claims tended to be earlier in the year when patients did not have insurance 
coverage, they may have paid the cash price for their medication(s). Another 
possibility regarding pay type is that patients may be in and out of the work force 
throughout the year, gaining and losing insurance coverage for a certain period.  
This may have also increased the percentage of cash payers in the population. 
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Another limitation involves lack of distinction of different CNS 
depressants classes. This study first started by creating depressant groups based 
on therapeutic class code, but did not differentiate by class or by the drug itself. 
Conducting a study based upon individual drugs was beyond the scope of this 
research, but could be considered for future investigation. 
This study has several strengths, primarily that it was the first study based 
on the RI PDMP which sought to discover relationships between chronic 
concomitant therapy of controlled substance CNS stimulants with CNS 
depressants and underlying demographics. One relationship was the average days’ 
supply, comparing the overlap cohort with that of those who only take stimulants. 
The other relationship was whether there was a difference in average daily dose 
for patients who had claims for both stimulants and depressants compared with 
those who had claims only for ADHD stimulants. By researching these two 
relationships, forward-looking hypotheses of interest can be developed. 
One potential hypothesis would question the importance of time to 
diagnosis for a health condition regarding another health condition. The patient 
could be followed in time to see if doses increase (or decrease) on average over 
time. For example, if a patient begins taking a CNS depressant, such as an opioid 
for a pain syndrome, do they also begin taking a stimulant? How long after 
initiation does this concomitant therapy begin? If so, was this due to (1) excessive 
sedation from the opioid or (2) was this for an entirely separate and new 
diagnosis, for example, ADHD? Conversely, if a patient begins with a diagnosis 
of ADHD, and then develops insomnia, are the two health conditions related? 
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Was the added therapy part of treatment for an underlying sleep disorder, or was 
it to alter the effects of the ADHD stimulant? These relationships can add insight 
into whether patients are being treated for underlying diseases or to “medicate a 
medication”. 
This study was designed to help describe a subset of the RI population 
which chronically fills both stimulants and CNS depressants. The value of this 
study comes from its ability to lay groundwork for future research into combined 
utilization of stimulants and depressants. Future work could include researching 
specific medication combinations, i.e., methylphenidate with oxycodone, or 
zolpidem with mixed amphetamine salts. Future work may also include a data set 
which is more robust, and includes other patient demographics such as 
socioeconomic status, race/ethnicity, and comorbid conditions. 
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APPENDIX 1: TABLES 
Table 1. Baseline characteristics for Hypothesis 1. Comparison of patients with 
claims for both stimulants and depressants for 60 or more days (<15 days gap) 
“overlap yes” compared with patients with less than 60 days overlap (<15 days 
gap) “overlap no”. 
Characteristics Overlap Yes 
N=4,389 
Overlap No 
N=127,087 
P Value 
Recipient Age, Years, Mean ± SD 43.4 ± 13.1 48.6 ± 21.1 < .0001 
Recipient Female Gender, N (%) 
                  Male Gender, N (%) 
2,979 (67.9) 
1,410 (32.1) 
73,401 (57.8) 
53,670 (42.2) 
< .0001 
Paytype, N (%) 
                  Govt. Payer/Other 
                  Private pay 
                  Commercial Ins. 
 
   787 (18.0) 
1,440 (32.8) 
2,160 (49.2) 
 
25,929 (20.4) 
30,662 (24.1) 
70,494 (55.5) 
< .0001 
Note: SD: standard deviation. N: number of patients. Govt.: government or other 
payer. Ins.: insurance. 
 
 
Table 2. Baseline characteristics for Hypothesis 2 (excluding outliers). 
Comparison of patients with claims for both stimulants and depressants for 60 or 
more days (<15 days gap) compared to patients who filled only stimulants for 60 
or more days (<15 days gap). 
Note: ‡N= Two ‘paytype’ missing from missing data. †N= Three outliers 
removed. SD: standard deviation. N: number of patients. Govt.: government or 
other payer. Ins.: insurance.
Characteristics Stimulants and 
Depressants‡ 
N=4,386† 
Stimulants-only 
 N= 37,982 
P-Value 
Recipient Age, Years, Mean ± 
SD 
43.4 ± 13 29.3 ± 17 <.0001 
Recipient Female Gender, N (%) 
                  Male Gender, N (%) 
2,978 (67.9) 
1,408 (32.1) 
19,254 (50.7) 
18,728 (49.3) 
<.0001 
Paytype‡, N (%)  
                  Govt. Payer/Other 
                  Private Pay 
                  Commercial Ins. 
 
787 (17.9) 
1,437 (32.8) 
2,160 (49.3) 
 
5,857 (15.4) 
6,049 (15.9) 
26,076 (68.7) 
<.0001 
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Table 3. Model results for average days of supply more than 30 days versus less 
than and equal to 30 days. Comparison of patients with claims for both stimulants 
and depressants for 60 or more days (<15 days gap) compared with patients who 
filled only stimulants for 60 or more days (<15 days gap). 
 
Model Independent variables(s) MLE β AIC OR p-value
1 Overlap yes or no -0.6728 3711.082 0.510 0.383 0.680 <.0001
2 Overlap yes or no + age 3543.408 <.0001
overlap yes -0.2405 0.786 0.587 1.052 0.1061
age <=11 1.1541 3.171 1.473 6.829 0.0032
age 12-17 1.1751 3.238 1.606 6.532 0.001
age 26-64 -0.6695 0.512 0.358 0.732 0.0002
age 65+ -2.0584 0.128 0.083 0.197 <.0001
3 Overlap yes or no + sex: female 3704.254 <.0001
overlap yes -0.616 0.540 0.405 0.721 <.0001
sex: female -0.3447 0.708 0.563 0.892 0.0033
4 Overlap yes or no + paytype 3658.767 <.0001
overlap yes -0.4815 0.618 0.461 0.827 0.0012
paytype commercial 0.0365 1.037 0.732 1.469 0.8369
paytype private -0.914 0.401 0.279 0.576 <.0001
5 Overlap yes or no + age + sex: female 3545.284 <.0001
overlap yes -0.2388 0.788 0.588 1.055 0.1088
sex: female -0.0419 0.959 0.760 1.210 0.7244
age <=11 1.1439 3.139 1.455 6.774 0.0036
age 12-17 1.1668 3.212 1.590 6.488 0.0011
age 26-64 -0.6641 0.515 0.360 0.737 0.0003
age 65+ -2.0542 0.128 0.083 0.198 <.0001
6 Overlap yes or no + age + paytype 3527.796 <.0001
overlap yes -0.1939 0.824 0.614 1.104 0.1949
paytype commercial -0.00135 0.999 0.701 1.423 0.994
paytype private -0.5539 0.575 0.399 0.829 0.003
age <=11 1.1187 3.061 1.419 6.605 0.0044
age 12-17 1.1392 3.124 1.548 6.307 0.0015
age 26-64 -0.5625 0.570 0.397 0.818 0.0023
age 65+ -1.876 0.153 0.098 0.240 <.0001
7 Overlap yes or no + sex: female + paytype 3656.187 <.0001
overlap yes -0.4536 0.635 0.474 0.851 0.0024
sex: female -0.2507 0.778 0.617 0.981 0.0338
paytype commercial 0.0402 1.041 0.735 1.474 0.8211
paytype private -0.8772 0.416 0.289 0.598 <.0001
Independent variables(s) MLE β AIC OR p-value
Overlap yes or no + age + sex: female + paytype 3529.789 <.0001
overlap yes -0.1937 0.824 0.614 1.105 0.1956
sex: female -0.00959 0.990 0.784 1.251 0.9358
paytype commercial -0.00154 0.998 0.701 1.423 0.9932
paytype private -0.5534 0.575 0.399 0.829 0.0030
age <=11 1.1164 3.054 1.412 6.603 0.0045
age 12-17 1.1373 3.118 1.542 6.304 0.0015
age 26-64 -0.5614 0.570 0.397 0.820 0.0024
age 65+ -1.8751 0.153 0.098 0.240 <.0001
Note: MLE: Maximum Likelihood Estimate; AIC: Akaike’s information criterion; OR: Odds ratio
Confidence Interval
Models for Crude Average Days of Supply (</= or > 30 days)
Model for Adjusted Average Days of Supply (</= or > 30 days)
Confidence Interval
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Table 4. Baseline Characteristics of Hypothesis 3. Comparison of patients with 
claims for both ADHD stimulants and CNS depressants for 60 or more days (<15 
days gap) compared with patients who filled only ADHD stimulants for 60 or 
more days (<15 days gap). 
Note: SD: standard deviation. N: number of patients. Govt.: government or other 
payer. Ins.: insurance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Stimulants and 
Depressants 
N=3,493 
ADHD-stimulants 
 N= 28,589 
P-Value 
Recipient Age, Years, Mean ± SD 42.2 ± 13 27.4 ± 16 <.0001 
Recipient Female Gender, N (%) 
                  Male Gender, N (%) 
2,358 (67.5) 
1,135 (32.5) 
13,717 (48) 
14,872 (52) 
<.0001 
Paytype, N (%) 
                  Govt. Payer/Other 
                  Private Pay 
                  Commercial Ins. 
 
679 (19.4) 
1,142 (32.7) 
1,672 (47.9) 
 
5,086 (17.8) 
3,426 (12.0) 
20,077 (70.2) 
<.0001 
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Table 5. Model results for average daily dose above 25 mg versus less or equal to 
25 mg. Comparison of patients with claims for both ADHD stimulants and CNS 
depressants for 60 or more days (<15 days gap) compared with patients who filled 
only ADHD stimulants for 60 or more days (<15 days gap). 
 
Model Independent variable(s) MLE β AIC OR p-value
1 Overlap yes or no -1.0198 43726.624 0.361 0.334 0.389 <.0001
2 Overlap yes or no + age 41388.635 <.0001
overlap yes -0.603 0.547 0.505 0.593 <.0001
age <=11 1.362 3.904 3.566 4.274 <.0001
age 12-17 0.2485 1.282 1.190 1.381 <.0001
age 26-64 -0.4508 0.637 0.599 0.677 <.0001
age 65+ -0.072 0.931 0.802 1.079 0.341
3 Overlap yes or no + sex: female 43719.212 <.0001
overlap yes -1.0065 0.366 0.338 0.395 <.0001
sex: female -0.0697 0.933 0.892 0.975 0.0022
4 Overlap yes or no + paytype 43445.003 <.0001
overlap yes -0.9262 0.396 0.366 0.428 <.0001
paytype commercial -0.0986 0.906 0.854 0.961 0.001
paytype private -0.632 0.532 0.490 0.576 <.0001
5 Overlap yes or no + age + sex: female 41311.573 0.791
overlap yes -0.6222 0.537 0.496 0.581 <.0001
sex: female 0.2176 1.243 1.185 1.304 <.0001
age <=11 1.4171 4.125 3.765 4.52 <.0001
age 12-17 0.2909 1.338 1.241 1.442 <.0001
age 26-64 -0.4718 0.624 0.587 0.664 <.0001
age 65+ -0.0851 0.918 0.792 1.065 0.2613
6 Overlap yes or no + age + paytype 41305.782 0.0151
overlap yes -0.5584 0.572 0.528 0.620 <.0001
paytype commercial 0.0428 1.044 0.981 1.111 0.1777
paytype private -0.2885 0.749 0.689 0.816 <.0001
age <=11 1.3571 3.885 3.547 4.255 <.0001
age 12-17 0.239 1.270 1.178 1.369 <.0001
age 26-64 -0.4149 0.660 0.621 0.703 <.0001
age 65+ 0.0254 1.026 0.883 1.192 0.7403
7 Overlap yes or no+ sex: female + paytype 43441.831 <.0001
overlap yes -0.9166 0.400 0.370 0.432 <.0001
sex: female -0.052 0.949 0.908 0.993 0.0229
paytype commercial -0.098 0.907 0.855 0.962 0.0011
paytype private -0.628 0.534 0.492 0.579 <.0001
Independent variable(s) MLE β AIC OR p-value
Overlap yes or no + age + sex: female + paytype 41228.605 0.5624
overlap yes -0.5774 0.561 0.518 0.608 <.0001
sex: female 0.2181 1.244 1.185 1.305 <.0001
paytype commercial 0.0476 1.049 0.985 1.116 0.1343
paytype private -0.2846 0.752 0.691 0.819 <.0001
age <=11 1.4131 4.109 3.747 4.505 <.0001
age 12-17 0.2821 1.326 1.229 1.43 <.0001
age 26-64 -0.4357 0.647 0.608 0.688 <.0001
age 65+ 0.0134 1.013 0.872 1.178 0.862
Note: MLE: Maximum Likelihood Estimate; AIC: Akaike’s information criterion; OR: Odds ratio
Confidence Interval
Models for Crude Average Daily Dose (</= or > 25 mg)
Model for Adjusted Average Daily Dose (</= or > 25 mg)
Confidence Interval
 
 
32 
 
Table 6. List of stimulant and CNS depressant medications filled, with frequency 
(count) and percent, by those who chronically fill stimulants and/or depressants. 
 
Stimulant Medications 
Frequen
cy Percent 
MIXED AMPHETAMINE 
(all dosage forms) 188,455 25.07 
METHYLPHENIDATE 76624 19.33 
VYVANSE 33952 8.56 
DEXTROAMPHETAMINE 27294 6.88 
PHENTERMINE 14405 3.63 
DEXTROAMPHETAMINE 11761 2.97 
DEXMETHYLPHENIDATE 9034 2.28 
PHENDIMETRAZINE 5269 1.33 
FOCALIN XR 3942 0.99 
MODAFINIL 3727 0.94 
CONCERTA 2757 0.7 
NUVIGIL 2640 0.67 
DEXTROAMPHETAMINE 
SPANSULE 2406 0.61 
QUILLIVANT 1217 0.31 
DAYTRANA 936 0.24 
ADIPEX-P 849 0.21 
RITALIN LA 578 0.15 
BELVIQ 555 0.14 
XYREM 542 0.14 
METADATE ER 422 0.11 
METADATE CD 387 0.1 
QSYMIA 343 0.09 
RITALIN 330 0.08 
PROVIGIL 216 0.05 
DEXEDRINE SPANSULE 157 0.04 
DIETHYLPROPION 145 0.04 
FOCALIN 131 0.03 
EVEKEO 51 0.01 
BENZPHETAMINE 36 0.01 
METHAMPHETAMINE 33 0.01 
METHYLIN 25 0.01 
MORPHINE SUL 21 0.01 
 
 
33 
 
DESOXYN 16 0 
ZENZEDI 14 0 
APTENSIO XR 9 0 
RITALIN-SR 8 0 
BONTRIL PDM 6 0 
METHYLIN ER 5 0 
PROCENTRA 5 0 
SUPRENZA 3 0 
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CNS Depressant 
Medications Frequency Percent 
CLONAZEPAM 188451 14.93 
OXYCODONE 173206 13.72 
ALPRAZOLAM 157466 12.48 
HYDROCODONE 152217 12.06 
ZOLPIDEM 134382 10.65 
LORAZEPAM 129990 10.3 
DIAZEPAM 53940 4.27 
MORPHINE SUL 34015 2.7 
OXYCONTIN 30497 2.42 
SUBOXONE 25514 2.02 
TEMAZEPAM 24499 1.94 
BUTALBITAL-COMBO 22183 1.76 
BUPRENORPHINE 18534 1.47 
APAP W/ CODEINE 13609 1.08 
PHENOBARBITAL 13275 1.05 
CARISOPRODOL 12546 0.99 
FENTANYL 10104 0.8 
METHADONE H 8386 0.66 
HYDROMORPHONE 8228 0.65 
FENTANYL 
TRANSDERMAL 6946 0.55 
ESZOPICLONE 6939 0.55 
ZALEPLON 3285 0.26 
TRIAZOLAM 3110 0.25 
CLORAZEPATE 2942 0.23 
LORAZEPAM I 2257 0.18 
LYRICA 1808 0.14 
ZUBSOLV 1569 0.12 
ENDOCET 1534 0.12 
BUTRANS 1397 0.11 
DRONABINOL 1338 0.11 
CHLORDIAZEPOXIDE 1283 0.1 
OPANA ER 1104 0.09 
OXYMORPHONE 1071 0.08 
BELSOMRA 981 0.08 
ONFI 895 0.07 
OXAZEPAM 827 0.07 
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NUCYNTA 592 0.05 
FLURAZEPAM 560 0.04 
XANAX 526 0.04 
NUCYNTA ER 506 0.04 
ASCOMP W/CODEINE 476 0.04 
VICODIN 450 0.04 
DIAZEPAM RECTAL 449 0.04 
VICODIN ES 443 0.04 
AMBIEN 440 0.03 
BUTORPHANOL 394 0.03 
OPIUM 387 0.03 
CODEINE SUL 359 0.03 
KLONOPIN 341 0.03 
PENTAZOCINE 321 0.03 
LUNESTA 279 0.02 
PERCOCET 279 0.02 
VALIUM 262 0.02 
BUTALBITAL/COMBO 260 0.02 
FYCOMPA 235 0.02 
GUAIFENESIN 234 0.02 
HYSINGLA ER 218 0.02 
DURAGESIC 207 0.02 
MEPROBAMATE 204 0.02 
PROMETHAZINE 199 0.02 
AMBIEN CR 196 0.02 
ATIVAN 194 0.02 
MEPERIDINE 191 0.02 
VIMPAT 190 0.02 
CHERATUSSIN 161 0.01 
EMBEDA 160 0.01 
XARTEMIS XR 158 0.01 
VICODIN HP 153 0.01 
HYDROMET 137 0.01 
EXALGO 101 0.01 
FIORICET 98 0.01 
NORCO 95 0.01 
ESTAZOLAM 75 0.01 
FIORINAL 60 0 
KADIAN 59 0 
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FENTANYL CITRATE 54 0 
BUNAVAIL 52 0 
NOVAPLUS FE 50 0 
INTERMEZZO 45 0 
MS CONTIN 43 0 
ROXICODONE 43 0 
DONNATAL 42 0 
MIDAZOLAM H 41 0 
ZOHYDRO ER 41 0 
FIORICET W CODEINE 39 0 
BUTISOL SOD 37 0 
CAPACET 36 0 
AVINZA 34 0 
DILAUDID 33 0 
SUBSYS 31 0 
ESGIC 30 0 
TYLENOL W/ CODEINE 29 0 
LAZANDA 28 0 
ORAL TRANSMUCOSAL 
FENTANYL 28 0 
BELLADONNA/COMBO 27 0 
KETAMINE 27 0 
XANAX XR 26 0 
DIASTAT ACUDIAL 23 0 
FENTORA 21 0 
LORTAB ELIXIR 21 0 
ISOMETHEPTENE, 
APAP, 
DICHLORALPHENAZONE 20 0 
SOMA 19 0 
DIAZEPAM IN 18 0 
LORTAB 10/3 17 0 
TRANXENE T 16 0 
XODOL 7.5/3 16 0 
BUPRENEX 14 0 
HALCION 14 0 
OXAYDO 14 0 
ROXICET 13 0 
SECONAL SOD 13 0 
 
 
37 
 
FIORINAL W/ CODEINE 9 0 
LEVORPHANOL 9 0 
CODEINE-GUAIFENESIN 8 0 
MARGESIC 8 0 
DEMEROL HYD 7 0 
METHADOSE 5 0 
MIDAZOLAM 5 0 
RESTORIL 5 0 
SONATA 5 0 
LORTAB 5/325 4 0 
GUAIATUSSIN 3 0 
EDLUAR 2 0 
INFUMORPH 2 0 
VIRTUSSIN A 2 0 
DEMEROL 1 0 
DOLOPHINE 1 0 
NODOLOR 1 0 
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APPENDIX 2: FIGURES 
Figure 1. Flow chart design for Overlap Yes vs. Overlap no cohorts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow chart design for comparison between stimulants and depressants 
cohort and stimulants only cohort. 
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one claim in PDMP in 2015 
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stimulant or CNS depressant (2015) 
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stimulant and CNS depressant with at 
least one overlapping day 
4,389 (1.1%) Patients who filled a 
stimulant and CNS depressant for at 
least 60 days overlapping with no 
more than a 15-day gap 
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one claim in PDMP in 2015 
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filled a stimulant(s) with or 
without depressant(s) 
37,982 (9.2%) Patients who 
filled a stimulant(s) only 
4,386 (1.1%) Patients who filled 
a stimulant(s) with a 
depressant(s) 
278,264 (67.9%) 
Patients excluded 
who did not fill a 
stimulant or 
depressant  
126,685 (30.9%) 
Patients excluded 
who filled for 0 
overlapping days 
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for between 0 and 
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who did not fill for a 
stimulant 
3 Patient outliers 
removed 
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Figure 3.  Percent of patients who filled for an average of ≤ 30 days or > 30 days. 
Comparison between those who filled both stimulants and depressants or 
stimulants only. An accompanying  
table of number of patients in each cohort is listed below. 
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Figure 4. Flow chart design comparison between ADHD stimulants only cohort 
and ADHD stimulants with depressants cohort. 
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Figure 5. Seven most commonly prescribed ADHD stimulant medications by base 
drug in Rhode Island in 2015. 
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Figure 6. Comparison of the percent of patients who filled for an average daily 
dose of less than or equal to 25 mg compared to those who filled for more than 25 
mg average daily dose, between those who filled both ADHD stimulants with 
depressants or ADHD stimulants only.  
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